RCMI Coordinating Center (RCMI CC) Header Logo

Robert L. Copeland

TitleAssociate Professor
Faculty RankAssociate Professor
InstitutionHoward University
DepartmentPharmacology
AddressHoward University
520 W. Street, N.W.
Washington DC 20059
Phone2028066311
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Robinson AGJ, Kanaan YM, Copeland RL. Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines. Anticancer Res. 2020 Dec; 40(12):6623-6635. PMID: 33288557.
      Citations:    
    2. Beyene DA, Daremipouran MR, Apprey V, Naab T, Kassim OO, Copeland RL, Kanaan YM. The Association Between the Genetic VDR SNP c.907+75C>T and Prostate Cancer Risk Is Modified by Tanning Potential. Cancer Genomics Proteomics. 2020 Nov-Dec; 17(6):739-745. PMID: 33099475.
      Citations:    Fields:    
    3. Tizabi Y, Getachew B, Copeland RL, Aschner M. Nicotine and the nicotinic cholinergic system in COVID-19. FEBS J. 2020 09; 287(17):3656-3663. PMID: 32790936.
      Citations: 1     Fields:    
    4. Getachew B, Csoka AB, Bhatti A, Copeland RL, Tizabi Y. Butyrate Protects Against Salsolinol-Induced Toxicity in SH-SY5Y Cells: Implication for Parkinson's Disease. Neurotox Res. 2020 Oct; 38(3):596-602. PMID: 32572814.
      Citations: 1     Fields:    
    5. Tizabi Y, Getachew B, Csoka AB, Manaye KF, Copeland RL. Novel targets for parkinsonism-depression comorbidity. Prog Mol Biol Transl Sci. 2019; 167:1-24. PMID: 31601399.
      Citations: 3     Fields:    Translation:Humans
    6. Daremipouran MR, Beyene D, Apprey V, Naab TJ, Kassim OO, Copeland RL, Kanaan YM. The Association of a Novel Identified VDR SNP With Prostate Cancer in African American Men. Cancer Genomics Proteomics. 2019 Jul-Aug; 16(4):245-255. PMID: 31243105.
      Citations: 1     Fields:    Translation:Humans
    7. Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell. 2019 07 08; 36(1):100-114.e25. PMID: 31257072.
      Citations: 9     Fields:    Translation:HumansCells
    8. Moses-Fynn E, Tang W, Beyene D, Apprey V, Copeland R, Kanaan Y, Kwabi-Addo B. Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men. PLoS One. 2018; 13(9):e0203322. PMID: 30204798.
      Citations: 3     Fields:    Translation:HumansCells
    9. Ren X, Ghassemi P, Kanaan YM, Naab T, Copeland RL, Dewitty RL, Kim I, Strobl JS, Agah M. Kernel-Based Microfluidic Constriction Assay for Tumor Sample Identification. ACS Sens. 2018 08 24; 3(8):1510-1521. PMID: 29979037.
      Citations: 3     Fields:    Translation:HumansCells
    10. Boriack-Sjodin PA, Ribich S, Copeland RA. RNA-modifying proteins as anticancer drug targets. Nat Rev Drug Discov. 2018 06; 17(6):435-453. PMID: 29773918.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    11. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659. PMID: 29650362.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    12. Drew AE, Moradei O, Jacques SL, Rioux N, Boriack-Sjodin AP, Allain C, Scott MP, Jin L, Raimondi A, Handler JL, Ott HM, Kruger RG, McCabe MT, Sneeringer C, Riera T, Shapiro G, Waters NJ, Mitchell LH, Duncan KW, Moyer MP, Copeland RA, Smith J, Chesworth R, Ribich SA. Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci Rep. 2017 12 21; 7(1):17993. PMID: 29269946.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    13. Copeland RL, Beyene D, Apprey V, Daremipouran MR, Naab TJ, Kassim OO, Kanaan YM. DHPLC Elution Patterns of VDR PCR Products Can Predict Prostate Cancer Susceptibility in African American Men. Cancer Genomics Proteomics. 2017 Nov-Dec; 14(6):461-467. PMID: 29109096.
      Citations: 1     Fields:    Translation:Humans
    14. Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic NM, Feldman I, Plescia C, Smith JJ, Copeland RA, Keilhack H, Chan-Penebre E, Knutson SK, Ribich SA, Raimondi A, Thomenius MJ. EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL. . 2017 11; 16(11):2586-2597. PMID: 28835384.
      Citations:    
    15. Owrang M, Copeland RL, Ricks-Santi LJ, Gaskins M, Beyene D, Dewitty RL, Kanaan YM. Breast Cancer Prognosis for Young Patients. In Vivo. 2017 Jul-Aug; 31(4):661-668. PMID: 28652435.
      Citations: 2     Fields:    Translation:Humans
    16. Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia. . 2017 08; 16(8):1669-1679. PMID: 28428443.
      Citations:    
    17. Riera TV, Wigle TJ, Copeland RA. Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method. Methods Mol Biol. 2016; 1439:33-45. PMID: 27316986.
      Citations:    
    18. Bamji ZD, Washington KN, Akinboye E, Bakare O, Kanaan YM, Copeland RL. Apoptotic Effects of Novel Dithiocarbamate Analogs of Emetine in Prostate Cancer Cell Lines. Anticancer Res. 2015 Sep; 35(9):4723-32. PMID: 26254362.
      Citations: 2     Fields:    Translation:HumansCells
    19. Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorg Med Chem. 2015 Sep 01; 23(17):5839-45. PMID: 26187015.
      Citations: 2     Fields:    Translation:HumansCells
    20. Winchester D, Ricks-Santi L, Mason T, Abbas M, Copeland RL, Beyene D, Jingwi EY, Dunston GM, Kanaan YM. SPINK1 Promoter Variants Are Associated with Prostate Cancer Predisposing Alterations in Benign Prostatic Hyperplasia Patients. Anticancer Res. 2015 Jul; 35(7):3811-9. PMID: 26124326.
      Citations: 1     Fields:    Translation:HumansCells
    21. Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015 Jun; 11(6):432-7. PMID: 25915199.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    22. Kassim OO, Copeland RL, Kenguele HM, Nekhai S, Ako-Nai KA, Kanaan YM. Antiproliferative activities of Fagara xanthoxyloides and Pseudocedrela kotschyi against prostate cancer cell lines. Anticancer Res. 2015 Mar; 35(3):1453-8. PMID: 25750297.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    23. Jingwi EY, Abbas M, Ricks-Santi L, Winchester D, Beyene D, Day A, Naab TJ, Kassim OO, Dunston GM, Copeland RL, Kanaan YM. Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men. Anticancer Res. 2015 Mar; 35(3):1549-58. PMID: 25750310.
      Citations: 11     Fields:    Translation:Humans
    24. Knutson SK, Warholic NM, Johnston LD, Klaus CR, Wigle TJ, Iwanowicz D, Littlefield BA, Porter-Scott M, Smith JJ, Moyer MP, Copeland RA, Pollock RM, Kuntz KW, Raimondi A, Keilhack H. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas. PLoS One. 2014; 9(12):e111840. PMID: 25493630.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    25. Beyene D, Daremipouran M, Apprey V, Williams R, Ricks-Santi L, Kassim OO, Naab TJ, Kanaan YM, Copeland RL. Use of tanning potential as a predictor for prostate cancer risk in African-American men. In Vivo. 2014 Nov-Dec; 28(6):1181-7. PMID: 25398820.
      Citations: 5     Fields:    Translation:Humans
    26. Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL, Gabrielson E, Dewitty RL. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics. 2014 Nov-Dec; 11(6):279-94. PMID: 25422359.
      Citations: 24     Fields:    Translation:HumansCells
    27. Klaus CR, Iwanowicz D, Johnston D, Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Scott MP, Pollock RM, Daigle SR, Raimondi A. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J Pharmacol Exp Ther. 2014 Sep; 350(3):646-56. PMID: 24993360.
      Citations: 35     Fields:    Translation:HumansCells
    28. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, Kadowaki T, Uesugi M, Kuznetsov G, Kumar N, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Waters NJ, Smith JJ, Porter-Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Uenaka T, Pollock RM, Kuntz KW, Yokoi A, Keilhack H. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. . 2014 Apr; 13(4):842-54. PMID: 24563539.
      Citations:    
    29. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 Aug 08; 122(6):1017-25. PMID: 23801631.
      Citations: 204     Fields:    Translation:HumansAnimalsCells
    30. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM, Kuntz KW, Keilhack H. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A. 2013 May 07; 110(19):7922-7. PMID: 23620515.
      Citations: 195     Fields:    Translation:HumansAnimalsCells
    31. Desai N, Copeland RA. Socioeconomic disparities in cataract surgery. Curr Opin Ophthalmol. 2013 Jan; 24(1):74-8. PMID: 23108314.
      Citations: 2     Fields:    Translation:Humans
    32. Basavapathruni A, Jin L, Daigle SR, Majer CR, Therkelsen CA, Wigle TJ, Kuntz KW, Chesworth R, Pollock RM, Scott MP, Moyer MP, Richon VM, Copeland RA, Olhava EJ. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Des. 2012 Dec; 80(6):971-80. PMID: 22978415.
      Citations: 35     Fields:    Translation:HumansCells
    33. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov; 8(11):890-6. PMID: 23023262.
      Citations: 287     Fields:    Translation:HumansCells
    34. Kaleem MA, Ramsahai S, Del Fierro K, Rasul S, Onumah C, Lerebours V, Gajjala J, Copeland RA, Jones LS. Ocular findings in human immunodeficiency virus patients in Washington, DC. Int Ophthalmol. 2012 Apr; 32(2):145-51. PMID: 22450559.
      Citations:    Fields:    Translation:HumansCells
    35. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12; 20(1):53-65. PMID: 21741596.
      Citations: 340     Fields:    Translation:HumansAnimalsCells
    36. Ferdinand L, Ngakeng V, Copeland RA. Corneal graft rejection in African Americans at Howard University Hospital. Saudi J Ophthalmol. 2011 Jul; 25(3):285-9. PMID: 23960938.
      Citations:    
    37. Yousuf SJ, Kumar N, Kidwell ED, Copeland RA. Rapidly fatal nasal natural killer/T-cell lymphoma: orbital and ocular adnexal presentations. Orbit. 2011 Mar; 30(2):120-1. PMID: 21438737.
      Citations: 2     Fields:    Translation:HumansCells
    38. Brandy Y, Ononiwu I, Adedeji D, Williams V, Mouamba C, Kanaan Y, Copeland RL, Wright DA, Butcher RJ, Denmeade SR, Bakare O. Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Invest New Drugs. 2012 Aug; 30(4):1709-14. PMID: 21243402.
      Citations: 4     Fields:    Translation:HumansCells
    39. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A. 2010 Dec 07; 107(49):20980-5. PMID: 21078963.
      Citations: 215     Fields:    Translation:HumansCells
    40. Kanaan YM, White DF, Das JR, Berhe S, Bakare O, Kenguele H, Beyene D, Zhou Y, Day AA, Copeland RL. Cytotoxic effects of N-(3-chloro-1,4-dioxo 1,4-dihydro-naphthalen-2-yl)-benzamide on androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2010 Feb; 30(2):519-27. PMID: 20332464.
      Citations:    Fields:    Translation:HumansCells
    41. Kanaan YM, Das JR, Bakare O, Enwerem NM, Berhe S, Beyene D, Williams V, Zhou Y, Copeland RL. Biological evaluation of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone as an anti-breast cancer agent. Anticancer Res. 2009 Jan; 29(1):191-9. PMID: 19331150.
      Citations: 7     Fields:    Translation:HumansCells
    42. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW, Yamashita DS, Choudhry AE, Copeland RA, Lai Z, Schaber MD, Tummino PJ, Strum SL, Wood ER, Duckett DR, Eberwein D, Knick VB, Lansing TJ, McConnell RT, Zhang S, Minthorn EA, Concha NO, Warren GL, Kumar R. Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem. 2008 Sep 25; 51(18):5663-79. PMID: 18800763.
      Citations: 37     Fields:    Translation:Animals
    43. Parrish CA, Adams ND, Auger KR, Burgess JL, Carson JD, Chaudhari AM, Copeland RA, Diamond MA, Donatelli CA, Duffy KJ, Faucette LF, Finer JT, Huffman WF, Hugger ED, Jackson JR, Knight SD, Luo L, Moore ML, Newlander KA, Ridgers LH, Sakowicz R, Shaw AN, Sung CM, Sutton D, Wood KW, Zhang SY, Zimmerman MN, Dhanak D. Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 04; 50(20):4939-52. PMID: 17725339.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    44. Tizabi Y, Bai L, Copeland RL, Taylor RE. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol. 2007 Sep-Oct; 42(5):413-6. PMID: 17686828.
      Citations: 45     Fields:    Translation:AnimalsCells
    45. Copeland RL, Das JR, Kanaan YM, Taylor RE, Tizabi Y. Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotox Res. 2007 Jul; 12(1):61-9. PMID: 17513200.
      Citations: 21     Fields:    Translation:HumansCells
    46. Copeland RL, Das JR, Bakare O, Enwerem NM, Berhe S, Hillaire K, White D, Beyene D, Kassim OO, Kanaan YM. Cytotoxicity of 2,3-dichloro-5,8-dimethoxy-1,4-naphthoquinone in androgen-dependent and -independent prostate cancer cell lines. Anticancer Res. 2007 May-Jun; 27(3B):1537-46. PMID: 17595773.
      Citations: 8     Fields:    Translation:HumansCells
    47. Copeland RL, Leggett YA, Kanaan YM, Taylor RE, Tizabi Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson's disease. Neurotox Res. 2005 Nov; 8(3-4):289-93. PMID: 16371323.
      Citations: 17     Fields:    Translation:HumansCells
    48. Kopcho LM, Ma J, Marcinkeviciene J, Lai Z, Witmer MR, Cheng J, Yanchunas J, Tredup J, Corbett M, Calambur D, Wittekind M, Paruchuri M, Kothari D, Lee G, Ganguly S, Ramamurthy V, Morin PE, Camac DM, King RW, Lasut AL, Ross OH, Hillman MC, Fish B, Shen K, Dowling RL, Kim YB, Graciani NR, Collins D, Combs AP, George H, Thompson LA, Copeland RA. Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme. Arch Biochem Biophys. 2003 Feb 15; 410(2):307-16. PMID: 12573291.
      Citations:    Fields:    Translation:HumansAnimalsCells
    49. Tizabi Y, Copeland RL, Louis VA, Taylor RE. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res. 2002 Mar; 26(3):394-9. PMID: 11923594.
      Citations: 63     Fields:    Translation:Animals
    Copeland's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (266)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support